228 35

Cited 0 times in

The Korean Society for Neuro-Oncology (KSNO) Guideline for WHO Grade III Cerebral Gliomas in Adults: Version 2019.01

 Young Zoon Kim  ;  Chae-Yong Kim  ;  Jaejoon Lim  ;  Kyoung Su Sung  ;  Jihae Lee  ;  Hyuk-Jin Oh  ;  Seok-Gu Kang  ;  Shin-Hyuk Kang  ;  Doo-Sik Kong  ;  Sung Hwan Kim  ;  Se-Hyuk Kim  ;  Se Hoon Kim  ;  Yu Jung Kim  ;  Eui Hyun Kim  ;  In Ah Kim  ;  Ho Sung Kim  ;  Tae Hoon Roh  ;  Jae-Sung Park  ;  Hyun Jin Park  ;  Sang Woo Song  ;  Seung Ho Yang  ;  Wan-Soo Yoon  ;  Hong In Yoon  ;  Soon-Tae Lee  ;  Sea-Won Lee  ;  Youn Soo Lee  ;  Chan Woo Wee  ;  Jong Hee Chang  ;  Tae-Young Jung  ;  Hye Lim Jung  ;  Jae Ho Cho  ;  Seung Hong Choi  ;  Hyoung Soo Choi  ;  Je Beom Hong  ;  Do Hoon Lim  ;  Dong-Sup Chung  ;  KSNO Guideline Working Group\ 
 Brain Tumor Research and Treatment, Vol.7(2) : 63-73, 2019 
Journal Title
 Brain Tumor Research and Treatment 
Issue Date
Grade III Gliomas ; Guideline ; Korean Society for Neuro Oncology ; Practice
BACKGROUND: There was no practical guideline for the management of patients with central nervous system tumor in Korea in the past. Thus, the Korean Society for Neuro-Oncology (KSNO), a multidisciplinary academic society, developed the guideline for glioblastoma successfully and published it in Brain Tumor Research and Treatment, the official journal of KSNO, in April 2019. Recently, the KSNO guideline for World Health Organization (WHO) grade III cerebral glioma in adults has been established. METHODS: The Working Group was composed of 35 multidisciplinary medical experts in Korea. References were identified by searches in PubMed, MEDLINE, EMBASE, and Cochrane CENTRAL databases using specific and sensitive keywords as well as combinations of keywords. Scope of the disease was confined to cerebral anaplastic astrocytoma and oligodendroglioma in adults. RESULTS: Whenever radiological feature suggests high grade glioma, maximal safe resection if feasible is globally recommended. After molecular and histological examinations, patients with anaplastic astrocytoma, isocitrate dehydrogenase (IDH)-mutant should be primary treated by standard brain radiotherapy and adjuvant temozolomide chemotherapy whereas those with anaplastic astrocytoma, NOS, and anaplastic astrocytoma, IDH-wildtype should be treated following the protocol for glioblastomas. In terms of anaplastic oligodendroglioma, IDH-mutant and 1p19q-codeletion, and anaplastic oligodendroglioma, NOS should be primary treated by standard brain radiotherapy and neoadjuvant or adjuvant PCV (procarbazine, lomustine, and vincristine) combination chemotherapy. CONCLUSION: The KSNO's guideline recommends that WHO grade III cerebral glioma of adults should be treated by maximal safe resection if feasible, followed by radiotherapy and/or chemotherapy according to molecular and histological features of tumors.
Files in This Item:
T201905237.pdf Download
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Neurosurgery (신경외과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실) > 1. Journal Papers
Yonsei Authors
Kang, Seok Gu(강석구) ORCID logo https://orcid.org/0000-0001-5676-2037
Kim, Se Hoon(김세훈) ORCID logo https://orcid.org/0000-0001-7516-7372
Kim, Eui Hyun(김의현) ORCID logo https://orcid.org/0000-0002-2523-7122
Yoon, Hong In(윤홍인) ORCID logo https://orcid.org/0000-0002-2106-6856
Chang, Jong Hee(장종희) ORCID logo https://orcid.org/0000-0003-1509-9800
Cho, Jae Ho(조재호) ORCID logo https://orcid.org/0000-0001-9966-5157
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.